Bifogade filer
BioInvent to Host Virtual KOL Event on June 18, 2024, to discuss BioInvent’s lead candidates BI-1808 and BI-1206
Kurs
+3,62%
Likviditet
5,94 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-10-29 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-26 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-04-29 | N/A | Årsstämma |
| 2025-04-29 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-27 | 08:00 | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-06 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2024-05-03 | - | Årsstämma |
| 2024-04-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-30 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-28 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2023-04-27 | - | Årsstämma |
| 2023-04-26 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-22 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-07-12 | - | Extra Bolagsstämma 2022 |
| 2022-04-29 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2022-04-28 | - | Årsstämma |
| 2022-04-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-30 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-23 | - | Extra Bolagsstämma 2021 |
| 2021-02-23 | - | Bokslutskommuniké 2020 |
| 2020-12-14 | - | Split BINV 25:1 |
| 2020-11-27 | - | Extra Bolagsstämma 2020 |
| 2020-10-29 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-29 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2020-05-28 | - | Årsstämma |
| 2020-04-30 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2020-04-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2019-04-25 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-20 | - | Extra Bolagsstämma 2019 |
| 2019-02-25 | - | Bokslutskommuniké 2018 |
| 2018-10-24 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-25 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2018-04-24 | - | Årsstämma |
| 2018-04-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-01-30 | - | Bokslutskommuniké 2017 |
| 2017-10-26 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-26 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-18 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2017-05-17 | - | Årsstämma |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2017-01-24 | - | Extra Bolagsstämma 2017 |
| 2016-10-25 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-13 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2016-05-12 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-18 | - | Extra Bolagsstämma 2016 |
| 2016-02-17 | - | Bokslutskommuniké 2015 |
| 2015-10-22 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-22 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-23 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2015-04-22 | - | Årsstämma |
| 2015-04-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-18 | - | Bokslutskommuniké 2014 |
| 2014-10-23 | - | Kvartalsrapport 2014-Q3 |
| 2014-07-24 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-06 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-25 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2014-04-24 | - | Årsstämma |
| 2014-03-19 | - | Extra Bolagsstämma 2014 |
| 2014-02-20 | - | Bokslutskommuniké 2013 |
| 2013-10-24 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-25 | - | Kvartalsrapport 2013-Q2 |
| 2013-06-19 | - | Extra Bolagsstämma 2013 |
| 2013-04-26 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2013-04-25 | - | Årsstämma |
| 2013-04-25 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-21 | - | Bokslutskommuniké 2012 |
| 2012-10-18 | - | Kvartalsrapport 2012-Q3 |
| 2012-09-28 | - | Kapitalmarknadsdag 2012 |
| 2012-07-19 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-19 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-27 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2012-03-26 | - | Årsstämma |
| 2012-03-09 | - | Extra Bolagsstämma 2012 |
| 2012-02-09 | - | Bokslutskommuniké 2011 |
| 2011-11-08 | - | Kapitalmarknadsdag 2011 |
| 2011-10-13 | - | Kvartalsrapport 2011-Q3 |
| 2011-07-14 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-14 | - | Kvartalsrapport 2011-Q1 |
| 2011-03-25 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2011-03-24 | - | Årsstämma |
| 2011-02-10 | - | Bokslutskommuniké 2010 |
| 2010-10-14 | - | Kvartalsrapport 2010-Q3 |
| 2010-07-14 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-21 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2010-04-20 | - | Årsstämma |
| 2010-04-15 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-17 | - | Bokslutskommuniké 2009 |
| 2009-10-15 | - | Kvartalsrapport 2009-Q3 |
| 2009-07-15 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-22 | - | X-dag ordinarie utdelning BINV 0.00 SEK |
| 2009-04-21 | - | Årsstämma |
| 2009-04-16 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
TNFR2 and FcyRIIB are promising targets in immuno-oncology.
Lund, Sweden – May 24, 2024 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a virtual KOL event on Tuesday, June 18, 2024 from 9:00-10:45 AM ET/3-4:45 PM CEST to discuss the recently presented clinical efficacy and safety data from its lead candidates BI-1808 and BI-1206, and TNFR2 and FcyRIIB as promising targets in immuno-oncology. To register, click here.
Further details on the event to be announced.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on the social media platform X: @BioInvent.
For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com